Ares Capital Corporation Closes First Venture Finance Transaction with Respicardia, Inc.
08:00 EDT 6 Aug 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Ares Capital Corporation (NASDAQ: ARCC) announced today that it closed
its first venture finance transaction with Respicardia®, Inc., an early
stage company developing a medical device targeted to improve
respiratory and cardio...
Other Sources for this Article
Ares Capital Corporation
Carl Drake, (404) 814-5204
cdrake@aresmgmt.com
or
Respicardia,
Inc.
Bonnie Labosky, (952) 540-4470
blabosky@respicardia.com
More From BioPortfolio on "Ares Capital Corporation Closes First Venture Finance Transaction with Respicardia, Inc."
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
